MCID: ALL010
MIFTS: 55

Allergic Contact Dermatitis

Categories: Immune diseases, Skin diseases

Aliases & Classifications for Allergic Contact Dermatitis

Summaries for Allergic Contact Dermatitis

PubMed Health : 62 About allergic contact dermatitis: A number of chemical or herbal substances can irritate the skin. Redness, burning or itching are normal skin reactions, for instance, to aggressive cleaning agents. Allergic contact dermatitis (sometimes simply called “contact allergies”) is different, though. Here the immune system overreacts to certain substances – sometimes to very small amounts – that normally wouldn’t cause a reaction. Common examples include certain metals, scents and latex rubber. Contact allergies can lead to severe skin reactions. Unlike with many other kinds of allergies, the reaction doesn’t occur immediately, but after one to three days. And contact allergies develop gradually over a long period of time, as a result of repeated contact with the substance that triggers them. Some people are then no longer able to carry on doing the same kind of work as before.

MalaCards based summary : Allergic Contact Dermatitis, also known as dermatitis, allergic contact, is related to palladium allergic contact dermatitis and nickel allergic contact dermatitis. An important gene associated with Allergic Contact Dermatitis is IL31 (Interleukin 31), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Hydrocortisone acetate and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are hematopoietic system and cellular

Disease Ontology : 12 A contact dermititis that is an allergic skin reaction to foreign chemical or substances leading to red, itchy, weepy reaction where the skin has come into contact with a substance that the immune system recognizes as foreign.

KEGG : 36 Allergic contact dermatitis (ACD) is a T-cell mediated skin inflammation caused by repeated skin exposure to contact allergens. Although regarded as a dermatosis that is typically triggered by environmental factors, ACD may affect certain individuals more easily than others. A higher risk for polysensitization has been found for polymorphism in the TNFA (TNFA-308) and IL-16 (IL-16-295 C/C) genes.

Wikipedia : 74 Allergic contact dermatitis (ACD) is a form of contact dermatitis that is the manifestation of an... more...

Related Diseases for Allergic Contact Dermatitis

Diseases related to Allergic Contact Dermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 714)
# Related Disease Score Top Affiliating Genes
1 palladium allergic contact dermatitis 34.8 TNF IL17A IL10 CCL17
2 nickel allergic contact dermatitis 34.5 SELE IL5 IL4 IL10 IFNG CD4
3 toxicodendron dermatitis 33.1 TNF SELE ICAM1 CXCL8
4 pustulosis of palm and sole 31.6 TNF IL17A CXCL8
5 ige responsiveness, atopic 31.4 IL5 IL4 IL10 IFNG
6 urticaria 31.2 TNF SELE IL6 IL5 IL4 IL31
7 irritant dermatitis 31.1 TNF IL6 IL4 IL31 FLG CXCL8
8 exanthem 31.1 TNF IL6 IL10 CXCL8 CD4
9 seborrheic dermatitis 31.0 TNF FLG CXCL8 CD4
10 metal allergy 30.9 IL4 IL17A IL10 CD4
11 rosacea 30.9 TNF IL6 IL33 CXCL8
12 neurofibromatosis, type ii 30.9 TNF IL6 CXCL8
13 actinic prurigo 30.8 TNF SELE ICAM1
14 herpes zoster 30.8 TNF IL10 IFNG CD4
15 acute generalized exanthematous pustulosis 30.8 IL17A CXCL8
16 pulpitis 30.8 TNF IL6 CXCL8
17 latex allergy 30.7 TNF IL5 IL4 IFNG FLG
18 stevens-johnson syndrome/toxic epidermal necrolysis 30.6 IL5 IFNG CXCR3 CCL22 CCL17
19 dermatitis, atopic, 8 30.6 IL10 CXCL8
20 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.6 IL17A IL10 IFNG
21 blepharoconjunctivitis 30.6 IL4 CXCL8 CD4
22 crohn's colitis 30.5 TNF IFNG CXCL8
23 sarcoidosis 1 30.5 TNF IFNG ICAM1 CXCR3 CD4
24 vasculitis 30.5 TNF SELE IL6 IL17A ICAM1
25 corticosteroid allergy 30.4 IL5 IL4 IFNG FLG CD4
26 septic arthritis 30.4 IFNG CXCR3 CXCL8
27 scabies 30.4 IL5 IL10 FLG CXCL8 CD4
28 folliculitis 30.3 IL5 IL4 IFNG CD4
29 tuberculoid leprosy 30.3 IL4 IL10 IFNG CD4
30 purpura 30.3 TNF IL6 IL4 IL10
31 varicose veins 30.3 TNF IL6 ICAM1 CXCL8
32 tetanus 30.3 TNF IL6 IL5 IL4 IL10 IFNG
33 thymoma 30.3 TNF IL6 IL4 IL17A
34 fasciitis 30.2 TNF IL6 IFNG CXCL8
35 mycosis fungoides 30.2 IL5 IFNG CXCR3 CCR4 CCR10 CCL22
36 cerebral palsy 30.2 TNF IL6 IL10 CXCL8
37 hypereosinophilic syndrome 30.2 IL5 IL4 IL10 IFNG CXCL8 CCL17
38 pertussis 30.2 TNF IL6 IL10 CXCL8
39 cellulitis 30.2 TNF IL6 IL5 IL10 CD4
40 blepharitis 30.1 TNF IL6 IL4 CXCL8 CD4
41 erythema multiforme 30.1 TNF IL6 IL5 IL4 IFNG ICAM1
42 sleep apnea 30.1 TNF IL6 IL10 ICAM1 CXCL8
43 viral hepatitis 30.1 TNF IL6 IL4 IL10 IFNG
44 gastritis 30.1 TNF IL6 IL17A IL10 CXCL8
45 severe acute respiratory syndrome 30.1 TNF IL6 IL10 IFNG CXCL8
46 gastroesophageal reflux 30.0 TNF IL6 IL5 IL4 CXCL8
47 conjunctivitis 30.0 TNF IL6 IL5 IL4 IL33 IL10
48 basal cell carcinoma 29.9 TNF IL6 IL10 ICAM1 CXCL8
49 human immunodeficiency virus type 1 29.9 TNF IL6 IL10 IFNG CD4 CCL27
50 stomatitis 29.8 TNF IL6 IL4 IL10 IFNG CXCL8

Graphical network of the top 20 diseases related to Allergic Contact Dermatitis:



Diseases related to Allergic Contact Dermatitis

Symptoms & Phenotypes for Allergic Contact Dermatitis

MGI Mouse Phenotypes related to Allergic Contact Dermatitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.24 CCL17 CCR10 CCR4 CD4 CXCR3 ICAM1
2 cellular MP:0005384 10.23 CCL17 CCR10 CD4 CXCR3 ICAM1 IFNG
3 immune system MP:0005387 10.22 CCL17 CCL22 CCR10 CCR4 CD4 CXCR3
4 digestive/alimentary MP:0005381 10.13 CD4 ICAM1 IFNG IL10 IL17A IL33
5 endocrine/exocrine gland MP:0005379 10.1 CCR10 CD4 ICAM1 IFNG IL10 IL17A
6 integument MP:0010771 10 CCR10 CD4 ICAM1 IFNG IL10 IL17A
7 neoplasm MP:0002006 9.7 CXCR3 ICAM1 IFNG IL10 IL5 IL6
8 no phenotypic analysis MP:0003012 9.5 CD4 IFNG IL10 IL17A IL33 IL4
9 respiratory system MP:0005388 9.36 CCR4 CXCR3 IFNG IL10 IL17A IL33

Drugs & Therapeutics for Allergic Contact Dermatitis

PubMed Health treatment related to Allergic Contact Dermatitis: 62

Allergic skin reactions are usually treated with steroid creams, ointments or solutions. But the main thing to do is avoid contact with the substance that triggers the reaction. Protective gloves and clothing can help here, for instance. A change of career may have to be considered if it isn’t possible to avoid contact with the substance in the workplace. If you are believed to have a work-related contact allergy , it’s a good idea to have your doctor inform your employer’s liability insurance. The insurance will cover certain costs, like the costs of protective measures, if the allergy is recognized as being work-related.

Drugs for Allergic Contact Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
2
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
3
Bronopol Approved Phase 4 52-51-7
4
Povidone Approved Phase 4 9003-39-8
5
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
6 Hydrocortisone hemisuccinate Phase 4
7 Hydrocortisone-17-butyrate Phase 4
8 Hydrocortisone 17-butyrate 21-propionate Phase 4
9 Antioxidants Phase 4
10 Antitubercular Agents Phase 4
11 Chelating Agents Phase 4
12 sodium thiosulfate Phase 4
13 Gold Sodium Thiosulfate Phase 4
14 Antidotes Phase 4
15 Antibodies, Monoclonal Phase 4
16 Antibodies Phase 4
17 Immunoglobulins Phase 4
18 Immunosuppressive Agents Phase 4
19 Immunologic Factors Phase 4
20 Anti-Inflammatory Agents Phase 4
21 Anti-Infective Agents Phase 4
22 Anti-Inflammatory Agents, Non-Steroidal Phase 4
23 Analgesics, Non-Narcotic Phase 4
24 Antirheumatic Agents Phase 4
25 Anti-Bacterial Agents Phase 4
26 Analgesics Phase 4
27 Angiogenesis Inhibitors Phase 4
28
Petrolatum Approved, Investigational Phase 3 8009-03-8
29
Silver sulfadiazine Approved, Vet_approved Phase 3 22199-08-2 441244
30
Sulfadiazine Approved, Investigational, Vet_approved Phase 3 68-35-9 5215
31 Dermatologic Agents Phase 3
32 Anti-Infective Agents, Local Phase 3
33 Emollients Phase 3
34 Antiparasitic Agents Phase 3
35 Antiprotozoal Agents Phase 3
36
Bacitracin Approved, Vet_approved Phase 2 1405-87-4 439542 10909430
37 Parthenolide Approved, Investigational Phase 2 20554-84-1
38
Minoxidil Approved, Investigational Phase 2 38304-91-5 4201
39 Pharmaceutical Solutions Phase 1, Phase 2
40 Phosphodiesterase 4 Inhibitors Phase 2
41 Antihypertensive Agents Phase 2
42 Vasodilator Agents Phase 2
43
Denosumab Approved Phase 1 615258-40-7
44
Squaric acid dibutyl ester Investigational Phase 1 2892-62-8
45 Adjuvants, Immunologic Phase 1
46
Betamethasone Approved, Vet_approved 378-44-9 9782
47 Grape Approved
48
Histamine Approved, Investigational 51-45-6 774
49
Methylprednisolone Approved, Vet_approved 83-43-2 6741
50
Methylprednisolone hemisuccinate Approved 2921-57-5

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 Clinical Evaluation of T.R.U.E. Test Panel 3.2 in Children and Adolescents (PREA II) Unknown status NCT01797562 Phase 4 T.R.U.E. Test Panel 3.2
2 An Open Single Centre Evaluation of the Reactivity of the T.R.U.E. Test Quaternium-15 Patch and a Real Use Exposure in Subjects Known to Be Allergic to Quaternium-15 Unknown status NCT00311454 Phase 4 T.R.U.E.Test
3 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Trial to Assess the Safety and Efficacy of 0.1% Tacrolimus Ointment in the Treatment of Chronic Allergic Contact Dermatitis Completed NCT00667056 Phase 4 tacrolimus ointment;placebo ointment
4 Clinical Evaluation of TRUE Test Ethylenediamine Dihydrochloride Allergen: Bioequivalence of Vehicle Formulations Completed NCT01798589 Phase 4 Ethylenediamine dihydrochloride
5 Clinical Evaluation of T.R.U.E. TEST® Panel 1.1, 2.1 and 3.1: in Children and Adolescents Completed NCT00795951 Phase 4
6 The Effects of Dupilumab on Allergic Contact Dermatitis Not yet recruiting NCT03935971 Phase 4 Dupilumab
7 An Open-label, Single-Arm Pilot Study Investigating the Efficacy and Safety of Apremilast for the Treatment of Moderate to Severe Chronic Hand Dermatitis Terminated NCT03741933 Phase 4 Apremilast 30mg
8 Anti-IL-17 a New Treatment for Contact Dermatititis Unknown status NCT02778711 Phase 3 secukinumab
9 A Randomized Controlled Clinical Trial Comparing The Efficacy and Safety of Open Dressing With Petrolatum Jelly vs. Standard Gauze Dressing With Silver Sulfadiazine in the Treatment of Filipino Adults Aged 18-45 Years Old With Superficial Partial Thickness Burns Less Than or Equal to 10% Total Surface Area Who Are Seen at the Philippine General Hospital Burn Outpatient Clinic Completed NCT02109718 Phase 3 Open Dressings with Petrolatum Jelly;Silver Sulfadiazine Gauze Dressing Group
10 An Efficacy and Safety Pilot Study Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Treatment of AGA Unknown status NCT01650272 Phase 1, Phase 2 5% MInoxidil milky lotion;5% Minoxidil solution
11 A Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of Three Weeks of Daily Dermal Application of MRX-6 (2% HyPE) on the Treatment of Mild to Moderate Contact Dermatitis of the Hand and Forearm Completed NCT00867607 Phase 1, Phase 2 MRX-6;Steroid
12 Clinical Evaluation of Bacitracin. A Phase II Dose-Response Study Completed NCT00132600 Phase 2 bacitracin (allergen)
13 A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Intradermal Injection of rHuPH20 or Placebo in Subjects With Nickel Allergic Contact Dermatitis Completed NCT00928447 Phase 2 rHuPH20;Placebo
14 Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate for ”TRUE Test® Panel 3” – a Phase II, Dose-Response Study. Completed NCT00133341 Phase 2 Goldnatriomthiosulphate, MDBGN, parthenolide
15 A Phase 2, Open-label, Investigator-Initiated Study to Evaluate the Safety and Efficacy of Apremilast in Subjects With Recalcitrant Contact or Atopic Dermatitis Completed NCT00931242 Phase 2 Apremilast
16 A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects With Chronic Allergic Contact Dermatitis Recruiting NCT03680131 Phase 2 EB01 Cream Placebo;EB01 Cream 0.2%;EB01 Cream 1.0%;EB01 Cream 2.0%
17 Clinical Treatment of Alopecia Areata With Stem Cell Educator Therapy and Oral Minoxidil Not yet recruiting NCT04011748 Phase 2
18 A Proof-of-Principle Study Investigating the Effect of Single Doses of NI-0801 on Nickel Induced Contact Dermatitis Completed NCT01244607 Phase 1 Placebo;NI-0801
19 Placebo-Controlled, Randomized, Parallel Group, Multiple-Dose Study to Evaluate the Effects of CP-481,715 on Clinical Response and Cellular Infiltration Following Contact Allergen Challenge to the Skin of Nickel Allergic Subjects. Completed NCT00141180 Phase 1 CP-481,715
20 Effect of RANKL Inhibition on UV-induced Immunosuppression Completed NCT01978483 Phase 1 Denosumab;Diphenylcyclopropenone;Normal Saline
21 A Phase I Study of the Immune Response to Herpes Simplex Virus Type 1 (HSV-1) and General Immune Health in Subjects Infected With HSV-1 Completed NCT03661541 Phase 1 Squaric Acid Dibutyl Ester
22 Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation Unknown status NCT00445029
23 Nickel Desensitization Using Topical Therapy Unknown status NCT01413477 Calcipotriol, Betamethasone, Calcipotriol & Betamethasone
24 Evaluating Results of Regularly Applied Emollient - Spray in Atopic Dermatitis Therapy Unknown status NCT02763722
25 Hand Eczema Trial: A Randomised Clinical Trial of the Effect of Classification and Individual Counselling Among Health Care Workers With Hand Eczema Unknown status NCT01012453
26 Oral Human Administration of Red Grape Polyphenol in Nickel-mediated Allergic Contact Dermatitis: an in Vitro Study Completed NCT03902392
27 Low Dose Exposure to Oxidized R-limonene - A Double Blinded Vehicle Controlled Repeated Open Application Test (ROAT) Study Completed NCT03313232
28 Epidemiology and Co-Reactivity of Novel Surfactant Allergens Completed NCT02534441
29 Analysis of Immune Reactions Occurring Upon Administration of Patch Tests and Contact Dermatitis Affected Skin Completed NCT01546298
30 Evaluation of the Clinical Implication of Short Repeated Nickel Exposures Completed NCT03309215
31 Intervention Study to Evaluate the Importance of Information Given to Patients With Contact Allergy Completed NCT01953380
32 Skin Prick Test in Healthy Volunteers of Any Sex, to Investigate the Potential Allergy to NeoMatriXTM Wound Matrix Completed NCT03522675
33 Oral Metal Contact Allergy: A Cause of Oral Squamous Cell Carcinoma? Completed NCT00693550
34 A Study to Determine if Tetrix Cream Impedes the Resolution of Experimentally Induced Allergic Contact Dermatitis Completed NCT00643214
35 Medrol® In Contact Dermatitis: A Prospective Study To Assess The Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Subjects Completed NCT00929981 Tablet Methylprednisolone (4 or 16 mg)
36 Molecular and Cellular Characterization of Spongiotic Dermatitis Completed NCT00371163
37 Contact Allergens Causing Chronic Urticaria in a New England-Area Population Completed NCT00868036
38 Switching to Powder Free Latex Gloves in the Entire OR as Part of a New ' Latex Safe' Protocol: a Safe Alternative? A Prospective, Observational Cohort Study Completed NCT02575053
39 Cutaneous and Systemic Reactions to Metal Implants: Utility of Patch Testing Prior and Post Placement of Metal Orthopedic Implants Recruiting NCT02483728
40 Quality of Life Assessment Before and After Hyposensitization Treatment in Systemic Nickel Allergy Syndrome Recruiting NCT03731494
41 Improving Value of Care for Patients With Severe Stasis Dermatitis Recruiting NCT03022786
42 An Investigator Initiated Study to Evaluate the Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions In Healthy Adult Male Subjects Not yet recruiting NCT03945760 Early Phase 1 Baricitinib;Placebo
43 Real-life Study to Assess the Incidence of Allergic Manifestations and Infectious Episodes in Healthy Term Infants at Risk of Dysbiosis During the First Year of Life Not yet recruiting NCT04182425
44 The Prevalence of Contact Allergies for Wound Dressings In Patients With Diabetic Foot Ulcers Not yet recruiting NCT04085705
45 RESTenosis in Patients With Contact ALLergy to Metals Zabrze Study Not yet recruiting NCT03588962
46 Defining a PGE2 Pathway in Regulating Eczema Not yet recruiting NCT04133506 Aspirin 300mg
47 Evaluation of the Therapeutic Effect and Local Tolerability of Elidel® Cream 1% (Pimecrolimus) in Chronic Discoid Lupus Erythematosus (dLE) or Subacute Cutaneous Lupus Erythematosus (scLE) Withdrawn NCT00222183 Elidel (pimecrolimus)

Search NIH Clinical Center for Allergic Contact Dermatitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


methdilazine
Methdilazine hydrochloride
Trimeprazine
trimeprazine tartrate

Cochrane evidence based reviews: dermatitis, allergic contact

Genetic Tests for Allergic Contact Dermatitis

Anatomical Context for Allergic Contact Dermatitis

MalaCards organs/tissues related to Allergic Contact Dermatitis:

40
Skin, Testes, T Cells, Lymph Node, Eye, Monocytes, B Cells

Publications for Allergic Contact Dermatitis

Articles related to Allergic Contact Dermatitis:

(show top 50) (show all 6566)
# Title Authors PMID Year
1
Molecular diagnostics of psoriasis, atopic dermatitis, allergic contact dermatitis and irritant contact dermatitis. 54 61
19818069 2010
2
Filaggrin mutations and allergic contact sensitization. 54 61
18478014 2008
3
Leukotriene B(4) enhances tumour necrosis factor-alpha-induced CCL27 production in human keratinocytes. 54 61
17581202 2007
4
Human arylamine N-acetyltransferase 2 polymorphism and susceptibility to allergic contact dermatitis. 54 61
16533241 2006
5
CCL22-induced responses are powerfully enhanced by synergy inducing chemokines via CCR4: evidence for the involvement of first beta-strand of chemokine. 54 61
15714581 2005
6
Th(1)/Th(2) responses to drugs. 54 61
11164989 2001
7
IL-4 enhances keratinocyte expression of CXCR3 agonistic chemokines. 54 61
10903743 2000
8
Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. 54 61
10886512 2000
9
The CXCR3 activating chemokines IP-10, Mig, and IP-9 are expressed in allergic but not in irritant patch test reactions. 54 61
10504443 1999
10
Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). 54 61
10233762 1999
11
IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. 54 61
9886425 1999
12
Interleukin-4 and the interleukin-4 receptor in allergic contact dermatitis. 54 61
9504244 1998
13
Pentoxifylline in vivo and in vitro down-regulates the expression of the intercellular adhesion molecule-1 in monocytes. 54 61
9155652 1997
14
4A11, a monoclonal antibody recognizing a novel antigen expressed on aberrant vascular endothelium. Upregulation in an in vivo model of contact dermatitis. 54 61
8311112 1994
15
Langerhans' cell expression of the selectin ligand, sialyl Lewis x. 54 61
7512530 1994
16
Effect of various metals on intercellular adhesion molecule-1 expression and tumour necrosis factor alpha production by normal human keratinocytes. 54 61
7864660 1994
17
[Immune mechanisms of atopic dermatitis]. 54 61
7507285 1993
18
Expression of adhesion molecules in early allergic patch test reactions. 54 61
1638065 1992
19
Keratinocyte expression of intercellular adhesion molecule 1 (ICAM-1) correlated with infiltration of lymphocyte function associated antigen 1 (LFA-1) positive cells in evolving allergic contact dermatitis reactions. 54 61
1682230 1991
20
Endothelial leucocyte adhesion molecule-1 (ELAM-1) expression in cutaneous inflammation. 54 61
1706195 1991
21
[Allergic contact dermatitis from a new dentin adhesive system]. 54 61
2151486 1990
22
[Contact dermatitis, due to (di)methacrylates, on the hands of dental personnel]. 54 61
2144665 1990
23
Expression of intercellular adhesion molecule-1 in murine allergic contact dermatitis. 54 61
1983170 1990
24
Mechanistic understanding of dendritic cell activation in skin sensitization: additional evidences to support potency classification. 61
31958493 2020
25
A Comprehensive Artificial Sweat Study for Quantitation of Nickel and Other Inorganic Elements Released from Imitation Earrings Purchased in Istanbul Market. 61
31940117 2020
26
12-year data on dermatologic cases in the Finnish Register of Occupational Diseases I: Distribution of different diagnoses and main causes of allergic contact dermatitis. 61
32037572 2020
27
Airborne allergic contact dermatitis due to acemetacin. 61
31617597 2020
28
Airborne allergic contact dermatitis caused by artichoke. 61
32017132 2020
29
Allergic contact dermatitis caused by a black rubber handbrake handle. 61
31566764 2020
30
Contact dermatitis caused by glucose sensors in diabetic children. 61
31657469 2020
31
Spinal GRPR and NPRA contribute to chronic itch in a murine model of allergic contact dermatitis. 61
32032577 2020
32
Bullous allergic contact dermatitis from disperse dyes in Lycra cycling shorts. 61
31566755 2020
33
Allergic contact dermatitis to decyl glucoside: Still an important allergen in Tinosorb M. 61
31566773 2020
34
Allergic contact dermatitis caused by tetrahydrofurfuryl acrylate in the adhesive of clip-on earrings. 61
31599966 2020
35
Allergic contact dermatitis due to neem oil: A case report and mini-review. 61
31823408 2020
36
Preventing relapses of airborne allergic contact dermatitis to isothiazolinones in wall paint by painting over with an isothiazolinone-free paint. 61
31587304 2020
37
Contact allergy to isothiazolinones epidemic: Current situation. 61
31515812 2020
38
Immune-competent in vitro co-culture models as an approach for skin sensitisation assessment. 61
31648045 2020
39
Proteomic analysis of haptenation by skin sensitisers: Diphencyprone and ethyl acrylate. 61
31669365 2020
40
The epidemic of methylisothiazolinone contact allergy in Europe: follow-up on changing exposures. 61
31419348 2020
41
Skin barrier damage after exposure to paraphenylenediamine. 61
31783056 2020
42
The implanted glucose monitoring system Eversense: An alternative for diabetes patients with isobornyl acrylate allergy. 61
31463958 2020
43
Isothiazolinones in cleaning products: Analysis with liquid chromatography tandem mass spectrometry of samples from sensitized patients and market. 61
31657463 2020
44
Paeoniflorin inhibits MRGPRX2-mediated pseudo-allergic reaction via calcium signaling pathway. 61
31667930 2020
45
Determining the role of allergic contact dermatitis in mycosis fungoides. 61
32009234 2020
46
Allergic contact dermatitis to triclosan-coated suture material. 61
31951289 2020
47
The value of pantomiming for allergic contact dermatitis. 61
31962091 2020
48
Allergic contact dermatitis caused by triethanolamine in an ultrasound gel. 61
31463962 2020
49
Allergic contact dermatitis caused by the elastic borders of diapers. 61
31566747 2020
50
Acrylate allergic contact dermatitis caused by hair prosthesis fixative. 61
31423595 2020

Variations for Allergic Contact Dermatitis

Expression for Allergic Contact Dermatitis

Search GEO for disease gene expression data for Allergic Contact Dermatitis.

Pathways for Allergic Contact Dermatitis

Pathways related to Allergic Contact Dermatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.1 TNF IL6 IL5 IL4 IL33 IL31
2
Show member pathways
13.93 TNF IL6 IL5 IL4 IL17A IL10
3
Show member pathways
13.67 TNF IL6 IL5 IL4 IL33 IL31
4
Show member pathways
13.65 TNF IL6 IL5 IL4 IL17A IL10
5
Show member pathways
13.52 TNF IL6 IL5 IL4 IL17A IL10
6
Show member pathways
13.48 TNF IL6 IL5 IL4 IL33 IL31
7
Show member pathways
13.47 ICAM1 CXCR3 CXCL8 CCR4 CCR10 CCL27
8
Show member pathways
13.34 TNF IL6 IL5 IL4 IL17A IL10
9
Show member pathways
13.02 CXCR3 CXCL8 CD4 CCR4 CCR10 CCL27
10
Show member pathways
12.99 TNF IL6 ICAM1 CXCL8 CD4 CCR4
11
Show member pathways
12.99 TNF IL6 IL5 IL4 IL17A IL10
12
Show member pathways
12.89 TNF IL6 IL33 IFNG ICAM1 CXCL8
13
Show member pathways
12.81 TNF IL6 IL33 IFNG CXCL8
14
Show member pathways
12.77 TNF IL6 IL5 IL4 IL17A IL10
15
Show member pathways
12.76 TNF IL6 IL5 IL4 IL17A IL10
16
Show member pathways
12.69 TNF IL4 IL10 IFNG CD4
17
Show member pathways
12.69 TNF IL6 IL17A IL10 IFNG CD4
18 12.63 TNF IL4 IL17A IL10 IFNG
19
Show member pathways
12.51 TNF IL6 IL5 IL4 IL17A IFNG
20
Show member pathways
12.45 IL6 IL5 IL4 IL10 IFNG
21
Show member pathways
12.43 TNF IL6 IL4 IFNG ICAM1
22
Show member pathways
12.43 TNF IL6 IL5 IL4 IL17A IL10
23 12.38 TNF IL6 ICAM1 CD4
24
Show member pathways
12.32 TNF IL4 IL10 IFNG
25
Show member pathways
12.32 TNF IL6 IL10 CCL22 CCL17
26 12.29 TNF IL6 IL10 IFNG
27
Show member pathways
12.29 TNF IL6 IL4 IFNG CXCL8
28
Show member pathways
12.29 TNF IL6 IL10 CXCR3 CXCL8 CCR4
29
Show member pathways
12.28 TNF IL6 IL33 CXCL8
30 12.24 TNF IL6 IL10 CXCL8
31
Show member pathways
12.23 TNF IL6 IL17A IL10 IFNG CD4
32 12.19 TNF IL6 IL4 IFNG ICAM1 CXCL8
33 12.18 TNF IL6 IL5 IL4 IL10 IFNG
34 12.16 TNF SELE IFNG ICAM1
35 12.15 TNF IL6 IL4 IL17A IL10 ICAM1
36
Show member pathways
12.11 TNF IL6 IL4 IFNG
37 12.09 TNF IL6 IL10 CXCL8
38 12.08 TNF IL6 IL10 IFNG CXCL8
39 12.06 TNF SELE IL6 ICAM1 CXCL8
40 12.06 TNF IL6 IL5 IL4 CD4
41 12.05 TNF SELE IL6 ICAM1
42 12.05 TNF IL6 IL17A IFNG ICAM1 CXCL8
43 11.99 SELE IL6 IL5 IL4 IFNG ICAM1
44
Show member pathways
11.97 IL6 IL17A ICAM1 CXCL8
45
Show member pathways
11.93 TNF IL5 IL4 IFNG CXCL8
46 11.91 TNF IL6 IL10 IFNG CD4
47 11.87 TNF IL6 IL10 CXCL8
48
Show member pathways
11.87 TNF SELE IL6 IFNG ICAM1 CXCL8
49 11.84 TNF IL6 IL5 IL4 CXCL8
50 11.82 IL6 IFNG CXCL8

GO Terms for Allergic Contact Dermatitis

Cellular components related to Allergic Contact Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 TNF IL6 IL5 IL4 IL33 IL31
2 external side of plasma membrane GO:0009897 9.7 TNF IL17A ICAM1 CXCR3 CD4 CCR4
3 membrane raft GO:0045121 9.56 TNF SELE ICAM1 CD4
4 extracellular space GO:0005615 9.5 TNF SELE IL6 IL5 IL4 IL33

Biological processes related to Allergic Contact Dermatitis according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.27 IL6 IL5 IL4 IL10 CXCR3 CXCL8
2 G protein-coupled receptor signaling pathway GO:0007186 10.23 CXCR3 CXCL8 CCR4 CCR10 CCL27 CCL22
3 positive regulation of transcription, DNA-templated GO:0045893 10.13 TNF IL6 IL5 IL4 IL10 CD4
4 positive regulation of gene expression GO:0010628 10.09 TNF IL6 IL4 IL33 IFNG
5 cell-cell signaling GO:0007267 10 IL17A CCL27 CCL22 CCL17
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.95 TNF ICAM1 CD4 CCL22 CCL17
7 cellular response to tumor necrosis factor GO:0071356 9.92 ICAM1 CXCL8 CCL22 CCL17
8 cellular response to lipopolysaccharide GO:0071222 9.92 TNF IL6 IL10 ICAM1 CXCL8
9 positive regulation of DNA-binding transcription factor activity GO:0051091 9.9 TNF IL6 IL5 IL10
10 inflammatory response GO:0006954 9.9 TNF SELE IL6 IL5 IL17A IL10
11 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.88 IL6 IL5 ICAM1 CD4
12 chemotaxis GO:0006935 9.87 CXCR3 CXCL8 CCR4 CCR10 CCL27 CCL22
13 response to glucocorticoid GO:0051384 9.86 TNF IL6 IL10
14 positive regulation of T cell proliferation GO:0042102 9.85 IL6 IL4 CD4
15 positive regulation of interleukin-6 production GO:0032755 9.85 TNF IL6 IL33
16 humoral immune response GO:0006959 9.85 TNF IL6 IFNG
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 TNF IL6 IL4 IFNG
18 cell chemotaxis GO:0060326 9.83 CXCR3 CCR4 CCR10 CCL27 CCL22
19 extrinsic apoptotic signaling pathway GO:0097191 9.82 TNF IL33 IFNG
20 positive regulation of nitric oxide biosynthetic process GO:0045429 9.82 TNF IFNG ICAM1
21 monocyte chemotaxis GO:0002548 9.81 IL6 CCL22 CCL17
22 calcium-mediated signaling GO:0019722 9.8 SELE CXCR3 CXCL8 CCR4 CCR10
23 negative regulation of endothelial cell apoptotic process GO:2000352 9.79 IL4 IL10 ICAM1
24 cellular response to interleukin-1 GO:0071347 9.77 IL17A ICAM1 CXCL8 CCL22 CCL17
25 positive regulation of JAK-STAT cascade GO:0046427 9.76 TNF IL6 IL5 IL10
26 positive regulation of osteoclast differentiation GO:0045672 9.73 TNF IL17A IFNG
27 chemokine-mediated signaling pathway GO:0070098 9.73 CXCR3 CXCL8 CCR4 CCR10 CCL22 CCL17
28 positive regulation of chemokine biosynthetic process GO:0045080 9.71 TNF IFNG
29 negative regulation of amyloid-beta clearance GO:1900222 9.7 TNF IFNG
30 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.7 IL4 IL10
31 positive regulation of interleukin-13 production GO:0032736 9.7 IL4 IL33
32 cytokine-mediated signaling pathway GO:0019221 9.7 TNF IL6 IL5 IL4 IL31 IL17A
33 negative regulation of lipid storage GO:0010888 9.69 TNF IL6
34 positive regulation of neuroinflammatory response GO:0150078 9.69 TNF IL6 IL33
35 endothelial cell apoptotic process GO:0072577 9.68 TNF IL10
36 negative regulation of cytokine secretion involved in immune response GO:0002740 9.67 TNF IL10
37 neuroinflammatory response GO:0150076 9.67 IL4 IFNG
38 positive regulation of immunoglobulin secretion GO:0051024 9.67 IL6 IL5 IL33
39 positive regulation of mononuclear cell migration GO:0071677 9.66 TNF CCL27
40 type 2 immune response GO:0042092 9.66 IL4 IL10
41 positive regulation of interleukin-23 production GO:0032747 9.65 IL17A IFNG
42 positive regulation of MHC class II biosynthetic process GO:0045348 9.65 IL4 IL10 IFNG
43 positive regulation of cellular respiration GO:1901857 9.63 IL4 IFNG
44 regulation of isotype switching GO:0045191 9.63 IL4 IL10
45 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.61 TNF IFNG
46 receptor biosynthetic process GO:0032800 9.61 TNF IL10
47 positive regulation of vitamin D biosynthetic process GO:0060557 9.59 TNF IFNG
48 positive regulation of nitrogen compound metabolic process GO:0051173 9.58 TNF IFNG
49 immune response GO:0006955 9.5 TNF IL6 IL5 IL4 IL17A IL10

Molecular functions related to Allergic Contact Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.39 TNF SELE IL6 IL5 IL4 IL33
2 growth factor activity GO:0008083 9.71 IL6 IL5 IL4 IL10
3 chemokine binding GO:0019956 9.54 CXCR3 CCR4 CCR10
4 C-C chemokine binding GO:0019957 9.5 CXCR3 CCR4 CCR10
5 C-C chemokine receptor activity GO:0016493 9.43 CXCR3 CCR4 CCR10
6 cytokine activity GO:0005125 9.4 TNF IL6 IL5 IL4 IL33 IL31
7 chemokine receptor activity GO:0004950 9.33 CXCR3 CCR4 CCR10
8 chemokine activity GO:0008009 9.26 CXCL8 CCL27 CCL22 CCL17

Sources for Allergic Contact Dermatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....